Azin Vakilpour
Overview
Explore the profile of Azin Vakilpour including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Onoue T, Matthews A, Vakilpour A, Kang Y, Lefebvre B, Smith A, et al.
Cardiooncology
. 2024 Nov;
10(1):75.
PMID: 39487530
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury. Our objectives were to report...
2.
Vakilpour A, Amini-Salehi E, Moghadam A, Keivanlou M, Letafatkar N, Habibi A, et al.
Nutr Diabetes
. 2024 Aug;
14(1):67.
PMID: 39164265
No abstract available.
3.
Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, et al.
Arch Med Res
. 2024 Aug;
55(6):103043.
PMID: 39094335
Background: Nonalcoholic fatty liver disease (NAFLD) is a global health challenge, with a rising rate in line with other metabolic diseases. We aimed to assess the global prevalence of NAFLD...
4.
Bhasin V, Vakilpour A, Scherrer-Crosbie M
Curr Oncol Rep
. 2024 Jul;
26(10):1197-1204.
PMID: 39002055
Purpose Of Review: The aim of this review is two-fold: (1) To examine the mechanisms by which statins may protect from anthracycline-induced cardiotoxicity and (2) To provide a comprehensive overview...
5.
Daskareh M, Vakilpour A, Barzegar-Golmoghani E, Esmaeilian S, Gilanchi S, Ezzati F, et al.
Diagnostics (Basel)
. 2024 Jun;
14(11).
PMID: 38893708
Background: The early diagnosis and treatment of rheumatoid arthritis (RA) are essential to prevent joint damage and enhance patient outcomes. Diagnosing RA in its early stages is challenging due to...
6.
Vakilpour A, Amini-Salehi E, Moghadam A, Keivanlou M, Letafatkar N, Habibi A, et al.
Nutr Diabetes
. 2024 May;
14(1):25.
PMID: 38729941
Background: Type 2 diabetes mellitus (T2DM) is a significant risk factor for non-alcoholic fatty liver disease (NAFLD). Increased fasting blood sugar (FBS), fasting insulin (FI), and insulin resistance (HOMA-IR) are...
7.
Amini-Salehi E, Nayak S, Maddineni G, Mahapatro A, Keivanlou M, Soltani Moghadam S, et al.
Ann Med Surg (Lond)
. 2024 May;
86(5):2900-2910.
PMID: 38694388
Background And Aim: Modulating the gut microbiota population by administration of probiotics, prebiotics, and synbiotics has shown to have a variety of health benefits in different populations, particularly those with...
8.
Lefebvre B, Kang Y, Vakilpour A, Onoue T, Frey N, Brahmbhatt P, et al.
JACC CardioOncol
. 2024 Jan;
5(6):747-754.
PMID: 38204993
Background: Previous retrospective studies have shown that chimeric antigen receptor T (CAR-T) cell therapy may be associated with major adverse cardiovascular events (MACE), especially in the context of cytokine-release syndrome...
9.
Vakilpour A, Lefebvre B, Lai C, Scherrer-Crosbie M
Blood Rev
. 2024 Jan;
64:101166.
PMID: 38182490
Cancer survivors are at significant risk of cardiovascular (CV) morbidity and mortality; patients with hematologic malignancies have a higher rate of death due to heart failure compared to all other...
10.
Ramezanzadeh E, Arzpeyma S, Vakilpour A, Abedi M, Hassanipour S
Caspian J Intern Med
. 2023 Nov;
14(4):668-675.
PMID: 38024183
Background: Endothelial dysfunction has a significant role in the pathogenesis of cardiovascular events in patients with kidney dysfunction. The present study aimed to compare the level of endothelial dysfunction in...